Mutant cells with altered sialic acid
The invention provides cells useful to propagate influenza virus mutants having reduced sialidase activity.
1. An isolated endogenously altered mutant mammalian or avian cell comprising decreased levels of N-acetylneuraminic acid and/or decreased levels of N-glycolylneuraminic acid relative to a corresponding wild-type cell which wild-type cell supports efficient influenza virus replication, wherein the mutant cell is selected from resistance to growth inhibition by a lectin which binds terminal sialic acid containing residues in sialic acid-containing host cell receptor, wherein the decreased levels of N-acetylneuraminic acid and/ or the decreased levels of N-glycolylneuraminic acid are not the result of exogenous sialidase treatment.
2. The isolated mutant cell of claim 1 which is a swine, bovine, simian or canine cell.
3. The isolated mutant cell of claim 1 wherein the wild-type cell is a Madin-Darby canine kidney (MDCK) cell.
4. The isolated mutant cell of claim 1 which is a mink cell.
5. The isolated mutant cell of claim 4 , wherein the mink cell is a mink lung cell.
6. The isolated mutant cell of claim 1 which has decreased levels of N-acetylneuraminic acid relative to said corresponding wild-type cell.
7. The isolated mutant cell of claim 1 which has decreased levels of N-glycolylneuraminic acid relative to said corresponding wild-type cell.
8. The isolated mutant cell of claim 1 which has decreased levels of N-acetylneuraminic acid and N-glycolylneuraminic acid relative to said corresponding wild-type cell.
9. The isolated mutant cell of claim 1 which has at least ten fold lower levels of N-acetylneuraminic acid and at least 2 fold lower levels of N-glycolylneuraminic acid relative to the corresponding wild-type cell.
10. The isolated mutant cell of claim 1 which is resistant to Maakia amurensis lectin and Sambucus nigra lectin.
11. The isolated mutant cell of claim 1 in which influenza virus with reduced sialidase activity efficiently replicates.
12. The isolated mutant cell of claim 1 wherein the lectin specifically binds sialic acid linked to galactose by α(2–3) or α(2∝6) linkage.
13. The isolated mutant cell of claim 1 wherein the lectin specifically binds sialic acid linked to N-acetylgalactosamine by α(2–6) linkages.
14. An isolated endogenously altered mutant mammalian or avian cell comprising decreased levels of terminal sialic acid-containing host cell receptors for influenza virus relative to a corresponding wild-type cell which wild-type cell supports efficient influenza virus replication, wherein the mutant cell is resistant to growth inhibition by maakia amurensis lectin and/or Sambucus nigra lectin, wherein the decreased levels of sialic acid-containing host cell receptors are not the result of exogenous sialidase treatment.